Gemphire Therapeutics Inc’s presentation at the AASLD The Liver Meeting® 2018 in San Francisco.

News Release 2018.11.14

SMC announced that Gemphire Therapeutics Inc. presented results of a study using STAM model at poster presentation at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2018 in San Francisco, November 9 -13.

Title: “Gemcabene Regulates Hepatic Genes Associated with Inflammation and Fibrosis with Impact on Non-Alcoholic Fatty Liver Disease”